-+ 0.00%
-+ 0.00%
-+ 0.00%

Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMO

PUBT·10/18/2026 22:06:43
Listen to the news
Eikon Therapeutics Releases Updated Phase 2 Lung Cancer Trial Abstract Ahead of ESMO
  • Eikon Therapeutics will present seven abstracts covering four cancer drug candidates at ESMO in Madrid, beginning October 23, 2026.
  • October 26 presentations will cover updated EIK1001 combination-treatment results in advanced lung cancer, alongside the Phase 2/3 TeLuRide-008 study.
  • October 23 presentations will include updated EIK1003 solid-tumor data, initial prostate cancer findings, and initial EIK1004 results in advanced solid tumors.
  • EIK1005 presentations will cover preliminary safety, tolerability and pharmacokinetic findings on October 23, with an ePoster outlining its Phase 1/2 study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610181805PRIMZONEFULLFEED9847992) on October 18, 2026, and is solely responsible for the information contained therein.